Brief: ExpreS2ion: 12-Month Durability Data Announced For Abncov2 Phase II Clinical Trial
16/06/2023 08:50
June 16 (Reuters) - ExpreS2ion Biotech Holding AB EXPRS2.ST :
* 12-MONTH DURABILITY DATA ANNOUNCED FOR ABNCOV2 PHASE II CLINICAL TRIAL
* 12-MONTH FOLLOW-UP ANALYSIS FROM A SUBSET OF SUBJECTS ENROLLED IN A PHASE II CLINICAL
TRIAL OF
ABNCOV2 SHOWS HIGH PROTECTION LEVELS (>90%) AGAINST ORIGINAL WUHAN STRAIN AND PREVIOUS VARIANTS
OF CONCERN
Source text for Eikon: ID:nWkr3QwVVr
Further company coverage: EXPRS2.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on ExpreS2ion Biotech Holding AB
See all newsBrief: Expres2ion Biotech To Raise SEK 19.3 Million From Warrants And Share Issue
Brief: ExpreS2ion Reports Q2 Loss Of SEK 9.7 Million
Brief: Expres2ion Biotech Says DSMB Recommends Expanding 450 Μg Cohort
Brief: Expres2ion Biotech Holding Q1 2026 Operating Income SEK 6.87 Mln
Brief: Expres2ion Updates ES2B-C001 Phase I Programme and Reports Additional Preliminary Immunogenicity and Safety Observations